GTX (GTXI -12.7%) drops on a negative article from The Street's Adam Feuerstein, saying that Phase 3 studies of Enobosarm, its cancer-related muscle wasting drug, will fail. Feuerstein says that prior data shows that the treatment may be struggling to demonstrate both an increase muscle mass and improve muscle performance or function- which the FDA requires for approval.
GTX (GTXI -12.7%) drops on a negative article from The Street's Adam Feuerstein, saying that...
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs